Furthermore, western blotting, cell proliferation assays and anchorage-independent growth assays showed that FDXR KD in tamoxifen- or fulvestrant-resistant T47D and MCF7 cell lines inhibited CPT1A expression and decreased tumor cell growth (Figures 3C–R; Supplementary Figures 3A–D). Here, CPT1A is linked to neoplasm.